Results of Calando's targeted nanoparticles in preclinical cancer study
October 01, 2007 | Analyst Insight
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research (NASDAQ: ARWR), announced last week that a preclinical study of its nucleic acid nanoparticle delivery technology to target tumors in mice was...
About Lux Research
Lux Research is a leading provider of tech-enabled research and advisory solutions, helping clients drive growth through technology innovation. A pioneer in the research industry, Lux uniquely combines technical expertise and business insights with a proprietary intelligence platform, using advanced analytics and data science to surface true leading indicators. With quality data derived from primary research, fact-based analysis, and opinions that challenge traditional thinking, Lux clients are empowered to make more informed decisions today to ensure future success.